Hemab Therapeutics Holdings, Inc. (COAG) stock
COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$39.06+0.01 (+0.01%)
Close on Nov 17, 2026Market cap $1.82BP/E –Yield –
Hemab Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $24.64M | +91.4% |
| Q2 FY2026 | Jun 30, 2026 | $20.34M | +44.2% |
| Q1 FY2026 | Mar 31, 2026 | $19.46M | – |
| Q3 FY2025 | Sep 30, 2025 | $14.56M | – |
| Q2 FY2025 | Jun 30, 2025 | $12.87M | – |
| Q1 FY2025 | Mar 31, 2025 | $14.10M | – |
See a number that looks wrong?